There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things hampering psychiatric drug development. “We are still fully reliant on descriptive diagnoses that yield heterogeneous patient cohorts,” Steve Hyman told the audience at the European Congress of Neuropsychopharmacology (ECNP) Roadmap Meeting on Precision Psychiatry in Amsterdam in January. Read More

Immutep Ltd.’s stock on Australia’s Securities Exchange plummeted nearly 90% on March 13 on the news that its phase III TACTI-004 trial evaluating eftilagimod alfa (IMP-321, efti) in first-line non-small-cell lung cancer was discontinued due to futility. Read More

Newco Kyron Bio is showing its colors after sealing a research agreement with Servier SA, underpinning a claim that it has overcome one of the longest-running challenges of the biotech industry, and developing technology to precisely control the glycosylation of therapeutic proteins. Read More

Two biotech and three med-tech companies are slated for Kosdaq debuts this month, signaling a potential rebound for Korea financings in 2026. Kanaph Therapeutics Inc. will open with a ₩40 billion (US$26.99 million) raise and Imbiologics Corp. will debut with ₩52 billion. Additionally, Mezoo Co. Ltd., Cosmo Robotics Co. Ltd. and Recensmedical Inc. will launch IPOs. Read More

Otsuka Pharmaceutical Co. Ltd. reaped positive results from an open-label phase II study of repinatrabit (JNT-517) in adolescents with phenylketonuria (PKU), a rare disease marked by the inability to break down the amino acid phenylalanine. Read More

Biopharma deal value reached $61.17 billion in the first two months of 2026, roughly a 60% increase from the $38.11 billion logged in the same period of 2025 and marking the strongest early year total in BioWorld’s records. The surge was driven by unusually strong activity in both months, with $31.16 billion in January and $30.01 billion in February. Read More

Total raised in public, private and other financings of biopharma companies, comparing 2019-2026. Read More

Year-to-date money raised in public, private and other financings of biopharma companies. Read More

New hires and promotions in the biopharma and med-tech industries, including: 4basebio, Curanex, Biogene, Edgeone, Fujifilm, Halozyme, Helus, Ipsen, Kenai, Mesoblast, Mindmaze, Poolbeg, Preveceutical, Ratio. Read More

Biopharma and med-tech companies raising money in public or private financings, including: Combat Medical, Monteris, Valanx, Verano. Read More

Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Bridgebio, Capricor, Insulet, Intensity, Noah, Otsuka, Personalis, Prelude, Regenxbio, Solid, United. Read More

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Biomarin, Beaubrain, C2N, Circle, Eli Lilly, Enodia, Gyre, Kezar, Trinity, Zuellig. Read More

Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Atara, Johnson & Johnson, Pierre, Toro, Ultragreen, Xspray. Read More